Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dantrolene Sodium

FDA-approved product (capsule, oral), marketed as Dantrium, Dantrolene Sodium, Revonto and 1 more.

Registered studies
12
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dantrolene Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cerebral palsy
  • Fever
  • Malignant hyperthermia
  • Multiple sclerosis
  • Spasticity
  • Spinal cord injury
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dantrolene and derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

12registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dantrolene Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dantrolene Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dantrolene in Statin-induced Myopathy

    NCT06966843 · start 2027-10

    Registered record
    Registry ID
    NCT06966843
    Conditions
    Statins Induced Myopathy
    Interventions
    Dantrolene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-10
    Completion
    2030-03
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatins Induced Myopathy
    InterventionDantrolene; Placebo
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

    NCT04134845 · start 2020-08-21

    Registered record
    Registry ID
    NCT04134845
    Conditions
    Ventricular Tachycardia
    Interventions
    Dantrolene/Ryanodex; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-08-21
    Completion
    2025-08-29
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentricular Tachycardia
    InterventionDantrolene/Ryanodex; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery

    NCT03762109 · start 2019-07-29

    Registered record
    Registry ID
    NCT03762109
    Conditions
    Lumbar Spine Injury
    Interventions
    Dantrolene; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-29
    Completion
    2024-06-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLumbar Spine Injury
    InterventionDantrolene; Placebo Oral Tablet
    PhasePhase 2
    Registry statusCompleted

  • Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

    NCT03600376 · start 2018-08-19

    Registered record
    Registry ID
    NCT03600376
    Conditions
    Exertional Heat Stroke
    Interventions
    Ryanodex and Standard of Care; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-19
    Completion
    2019-08-14
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExertional Heat Stroke
    InterventionRyanodex and Standard of Care; Standard of Care
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

    NCT03189433 · start 2017-08-12

    Registered record
    Registry ID
    NCT03189433
    Conditions
    Drug Toxicity Psychotropic Agents Psychostimulants
    Interventions
    Ryanodex (dantrolene sodium) for injectable suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-08-12
    Completion
    2018-12-31
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Toxicity Psychotropic Agents Psychostimulants
    InterventionRyanodex (dantrolene sodium) for injectable suspension
    PhasePhase 2
    Registry statusTerminated

  • Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

    NCT03109288 · start 2017-08-11

    Registered record
    Registry ID
    NCT03109288
    Conditions
    Multiple Sclerosis
    Interventions
    Cilostazol; Leucovorin; Pirfenidone; Dantrolene; Pioglitazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2017-08-11
    Completion
    2029-01-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionCilostazol; Leucovorin; Pirfenidone; Dantrolene +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

    NCT02829268 · start 2017-01

    Registered record
    Registry ID
    NCT02829268
    Conditions
    Wolfram Syndrome; Diabetes Mellitus; Optic Nerve Atrophy; Ataxia
    Interventions
    dantrolene sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-01
    Completion
    2023-02
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWolfram Syndrome; Diabetes Mellitus; Optic Nerve Atrophy; Ataxia
    Interventiondantrolene sodium
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

    NCT02513095 · start 2015-09

    Registered record
    Registry ID
    NCT02513095
    Conditions
    Heat Stroke
    Interventions
    Dantrolene sodium for injectable suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09
    Completion
    2015-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeat Stroke
    InterventionDantrolene sodium for injectable suspension
    PhasePhase 2
    Registry statusCompleted

  • Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

    NCT01950520 · start 2014-02-07

    Registered record
    Registry ID
    NCT01950520
    Conditions
    Healthy Volunteers
    Interventions
    Propranolol; Pindolol; Dantrolene; Magnesium Sulfate; Caffeine; Qsymia; Topiramate; Phentermine; Naltrexone; Mirabegron 50mg; Mirabegron 200mg; Placebo Cohort 1; Placebo Cohort 2; Placebo for Mirabegron
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-02-07
    Completion
    2024-06-11
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPropranolol; Pindolol; Dantrolene; Magnesium Sulfate +10 more
    PhasePhase 2
    Registry statusCompleted

  • Safety Study of Dantrolene in Subarachnoid Hemorrhage

    NCT01024972 · start 2009-10

    Registered record
    Registry ID
    NCT01024972
    Conditions
    Subarachnoid Hemorrhage; Cerebral Vasospasm
    Interventions
    Dantrolene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2013-10
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Cerebral Vasospasm
    InterventionDantrolene; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)

    NCT00796900 · start 2008-05

    Registered record
    Registry ID
    NCT00796900
    Conditions
    Hyperthermia
    Interventions
    Dantrolene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2011-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperthermia
    InterventionDantrolene; Placebo
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage

    NCT00964548 · start 2007-07

    Registered record
    Registry ID
    NCT00964548
    Conditions
    Cerebral Vasospasm After Subarachnoid Hemorrhage
    Interventions
    Dantrolene; Dantrolene
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2009-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Vasospasm After Subarachnoid Hemorrhage
    InterventionDantrolene; Dantrolene
    PhasePhase 1 / Phase 2
    Registry statusCompleted